OraSure Technologies Sees Q3 Sales $29.500M-$32.500M vs $31.143M Est
OraSure Technologies (NASDAQ:OSUR) sees Q3 sales of $29.500 million-$32.500 million vs $31.143 million analyst estimate.
Read original at benzingaStocks · News reference
OraSure Technologies Receives FDA's Emergency Use Authorization For Its OraQuick Ebola 2.0 Rapid Antigen Test
OraSure Technologies, Inc. (NASDAQ:OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that it has received Emergency Use Authorization (EUA) from the
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 21, 2026, 8:31 PM
- Checked
- Jul 21, 2026, 8:31 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
OraSure Technologies Q2 Adj. EPS $(0.20) Beats $(0.27) Estimate, Sales $30.639M Beat $29.064M Estimate
Read original at benzingaCDC Raises Its Response Level To Congo Ebola Outbreak To Level 1 Activation, Its Highest Level; Says Risk Of Ebola Spreading In The U.S. Remains Low
Read original at benzinga